Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-553X (Electronic) Linking ISSN: 17515521 NLM ISO Abbreviation: Int J Lab Hematol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Blackwell Scientific Publications, c2007-
    • Subject Terms:
      Blood Coagulation/*drug effects ; Blood Coagulation Factors/*pharmacology ; Blood Coagulation Tests/*methods ; Carboxypeptidase B2/*pharmacology ; Fibrinogen/*pharmacology; Blood Coagulation Tests/instrumentation ; Blood Platelets/cytology ; Blood Platelets/drug effects ; Blood Platelets/metabolism ; Calcium Chloride/pharmacology ; Humans ; Models, Biological ; Primary Cell Culture ; Rotation ; Severity of Illness Index ; Thrombelastography/instrumentation ; Thrombocytopenia/blood ; Thrombocytopenia/pathology ; Tissue Plasminogen Activator/pharmacology
    • Abstract:
      Introduction: Bleeding symptoms in severe thrombocytopenia range from mild to severe. The aim of this in vitro study was to improve blood clotting and protect against fibrinolysis in reconstituted severe thrombocytopenia blood.
      Methods: Thrombocytopenia [(16 ± 4) × 10(6) /mL] was created by high-speed centrifugation of normal blood with subsequent mixing plasma with packed cells. The blood samples were subjected to clotting by CaCl2 and tissue factor and to fibrinolysis by the addition of tissue plasminogen activator. Blood was spiked with fibrinogen, activated prothrombin complex concentrate (FEIBA), thrombin activatable fibrinolysis inhibitor (TAFI), or their combinations. To mimic the situation that may occur in patients subjected to massive transfusion of plasma substitutes, blood was diluted by 40% of TRIS/saline buffer. Clotting time (CT), α-Angle, maximum clot firmness (MCF), and lysis onset time (LOT) were evaluated using rotation thromboelastometry.
      Results: Spiking thrombocytopenia blood with FEIBA led to reduction of CT. Fibrinogen and FEIBA enhanced α-Angle and MCF both in the absence and in the presence of tPA. LOT values were prolonged by TAFI and to less extent by FEIBA. Dilution of thrombocytopenia blood was followed by reduction of α-Angle and MCF compared to nondiluted blood which partly reversed by either fibrinogen or FEIBA being higher using fibrinogen and FEIBA together. Clot strength was enhanced, and fibrinolysis was inhibited by TAFI.
      Conclusion: The results of this study suggest that combined spiking of blood with fibrinogen and FEIBA may be enough to correct the clot formation disorder in severe thrombocytopenia, whereas in thrombocytopenia and blood dilution, additive inhibition of fibrinolysis may be needed.
      (© 2015 John Wiley & Sons Ltd.)
    • Contributed Indexing:
      Keywords: FEIBA; TAFI; Thrombocytopenia; fibrinogen; thromboelastometry
    • Accession Number:
      0 (Blood Coagulation Factors)
      37224-63-8 (prothrombin complex concentrates)
      9001-32-5 (Fibrinogen)
      EC 3.4.17.20 (Carboxypeptidase B2)
      EC 3.4.21.68 (Tissue Plasminogen Activator)
      M4I0D6VV5M (Calcium Chloride)
    • Publication Date:
      Date Created: 20150205 Date Completed: 20160412 Latest Revision: 20150716
    • Publication Date:
      20231215
    • Accession Number:
      10.1111/ijlh.12331
    • Accession Number:
      25651468